Allex Jardim da Fonseca1, Luiz Carlos de Lima Ferreira, Giacomo Balbinotto Neto. 1. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, AM, Brazil; Post-Graduate Program in Economics, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. Electronic address: allex.jardim@bol.com.br.
Abstract
OBJECTIVE: To assess the cost-utility of the human papillomavirus (HPV) vaccination on the prevention of cervical cancer in the Brazilian Amazon region. METHODS: A Markov cohort model was developed to simulate the natural evolution of HPV and its progress to cervical cancer, considering the current preventive programs and treatment costs. The one-year transition probabilities were mainly based on empirical data of local and national studies. The model evaluated the addition of the vaccine to three cervical cancer-screening scenarios (0, 3 or 10 exams throughout life). RESULTS: The scenario of three Pap tests resulted in satisfactory calibration (base case). The addition of HPV vaccination would reduce by 35% the incidence of cervical cancer (70% vaccination coverage). The incremental cost-effectiveness ratio was US$ 825 for each quality-adjusted life year gained. The sensitivity analysis confirms the robustness of this result, and duration of immunity was the parameter with greater variation in incremental cost-effectiveness ratio. CONCLUSION: Vaccination has a favorable profile in terms of cost-utility, and its inclusion in the immunization schedule would result in a substantial reduction in incidence and mortality of invasive cervical cancer in the Brazilian Amazon region.
OBJECTIVE: To assess the cost-utility of the human papillomavirus (HPV) vaccination on the prevention of cervical cancer in the Brazilian Amazon region. METHODS: A Markov cohort model was developed to simulate the natural evolution of HPV and its progress to cervical cancer, considering the current preventive programs and treatment costs. The one-year transition probabilities were mainly based on empirical data of local and national studies. The model evaluated the addition of the vaccine to three cervical cancer-screening scenarios (0, 3 or 10 exams throughout life). RESULTS: The scenario of three Pap tests resulted in satisfactory calibration (base case). The addition of HPV vaccination would reduce by 35% the incidence of cervical cancer (70% vaccination coverage). The incremental cost-effectiveness ratio was US$ 825 for each quality-adjusted life year gained. The sensitivity analysis confirms the robustness of this result, and duration of immunity was the parameter with greater variation in incremental cost-effectiveness ratio. CONCLUSION: Vaccination has a favorable profile in terms of cost-utility, and its inclusion in the immunization schedule would result in a substantial reduction in incidence and mortality of invasive cervical cancer in the Brazilian Amazon region.
Authors: Obinna I Ekwunife; James F O'Mahony; Andreas Gerber Grote; Christoph Mosch; Tatjana Paeck; Stefan K Lhachimi Journal: Pharmacoeconomics Date: 2017-01 Impact factor: 4.981
Authors: Ana Carolina Oliveira Gonçalves; Maurílio de Souza Cazarim; Cristina Sanches; Leonardo Regis Leira Pereira; Ana Márcia Tomé Camargos; Jéssica Azevedo Aquino; Andre Oliveira Baldoni Journal: BMJ Open Diabetes Res Care Date: 2019-07-16
Authors: Alessandro G Campolina; Tania Y Yuba; Tassia C Decimoni; Roseli Leandro; Maria Del Pilar Estevez Diz; Hillegonda M D Novaes; Patrícia C de Soárez Journal: Front Public Health Date: 2018-07-27